Marzena Dębska

Prof. Dr. Marzena Dębska

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2010 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
LGLéonardo Gucciardo
Léonardo Gucciardo
Liesbeth LewiLiesbeth Lewi
Liesbeth Lewi
PVPascal Vaast
Pascal Vaast
MDMarzena Dębska
Marzena Dębska
LCLuc De Catte
Luc De Catte
JDJan Deprest
Jan Deprest

12 November 2015 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Open access
PDF file
EBEwa Brojer
Ewa Brojer
AHAnne Husebekk
Anne Husebekk
MDMarzena Dębska
Marzena Dębska
MUMałgorzata Uhrynowska
Małgorzata Uhrynowska
KGKatarzyna Guz
Katarzyna Guz
KMKrystyna Maślanka
Krystyna Maślanka
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a relatively rare condition (1/1000–1/2000) that was granted orphan status by the European Medicines Agency in 2011. Clinical consequences of FNAIT, however, may be severe. A thrombocytopenic fetus or new-born is at risk of intracranial hemorrhage that may result in lifelong disability or death. Preventing such bleeding is thus vital and requires a solution. Anti-HPA1a antibodies are the most frequent cause of FNAIT in Caucasians. Its pathogenesis is similar to hemolytic disease of the newborn (HDN) due to anti-RhD antibodies, but is characterized by platelet destruction and is more often observed in the first pregnancy. In 75 % of these women, alloimmunization by HPA-1a antigens, however, occurs at delivery, which enables development of antibody-mediated immune suppression to prevent maternal immunization. As for HDN, the recurrence rate of FNAIT is high. For advancing diagnostic efforts and treatment, it is thereby crucial to understand the pathogenesis of FNAIT, including cellular immunity involvement. This review presents the current knowledge on FNAIT. Also described is a program for HPA-1a screening in identifying HPA-1a negative pregnant women at risk of immunization. This program is now performed at the Institute of Hematology and Transfusion Medicine in cooperation with the Department of Obstetrics and Gynecology of the Medical Centre of Postgraduate Education in Warsaw as well as the UiT The Arctic University of Norway.

8 January 2019 in Transfusion
Verified
Journal Article
Closed access
PDF file
AOAgnieszka Orzińska
Agnieszka Orzińska
KGKatarzyna Guz
Katarzyna Guz
MMMichal Mikula
Michal Mikula
AKAnna Kluska
Anna Kluska
ABAneta Balabas
Aneta Balabas
EBEwa Brojer
Ewa Brojer

1 September 2021 in Placenta
Verified
Journal Article
Open access
NNNora Hersoug Nedberg
Nora Hersoug Nedberg
GTGitta Turowski
Gitta Turowski
KGKatarzyna Guz
Katarzyna Guz
EPEwa Przytuła
Ewa Przytuła
MUMałgorzata Uhrynowska
Małgorzata Uhrynowska
HTHeidi Tiller
Heidi Tiller
Maternal alloimmunization against human platelet antigen (HPA)-1a has been implied to mediate both reduced birth weight and chronic placental inflammation. Fetal growth restriction is associated with different types of chronic inflammation in the placenta, mainly chronic histiocytic intervillositis and chronic villitis. The aim of this prospective study was to do a systematic examination of placentas from HPA-1a alloimmunized pregnancies, with focus on the histopathological and immunohistochemical diagnosis of variants of chronic inflammation. In a Polish-Norwegian study, 48 placentas were examined. The histopathology of placentas from 27 HPA-1a immunized women was compared with 21 placentas from non-immunized HPA-1a negative women (controls). In the group of alloimmunized women, ten received antenatal intravenous immunoglobulin G (IVIg). Tissue sections from formalin fixed paraffin embedded placental tissue were stained with hematoxylin and eosin and microscopically examined with focus on various types of chronic placental inflammations. Chronic histiocytic intervillositis was observed in 40.7% of placentas from HPA-1a alloimmunized pregnancies, compared to none in the control group (p = 0.001). Chronic villitis of unknown etiology was more frequently found in the alloimmunized group, however this difference was not statistically significant. Maternal administration of IVIg did not seem to protect against chronic inflammatory lesions. Placentas with detectable maternal anti-HPA-1a antibodies are associated with highly increased risk of low-grade chronic histiocytic intervillositis.

21 July 2020 in Journal of Perinatal Medicine
Verified
Journal Article
Closed access
OAOluş Api
Oluş Api
CSCihat Sen
Cihat Sen
MDMarzena Dębska
Marzena Dębska
GSGabriele Saccone
Gabriele Saccone
FDFrancesco D’aNtonio
Francesco D’aNtonio
FCFrank Chervenak
Frank Chervenak
These guidelines follow the mission of the World Association of Perinatal Medicine, which brings together groups and individuals throughout the world with the goal of improving outcomes of maternal, fetal and neonatal (perinatal) patients. Guidelines for auditing, evaluation, and clinical care in perinatal medicine enable physicians diagnose, treat and follow-up of COVID-19-exposed pregnant women. These guidelines are based on quality evidence in the peer review literature as well as the experience of perinatal expert throughout the world. Physicians are advised to apply these guidelines to the local realities which they face. We plan to update these guidelines as new evidence become available.

1 January 2018 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
MDMarzena Dębska
Marzena Dębska
MUMałgorzata Uhrynowska
Małgorzata Uhrynowska
KGKatarzyna Guz
Katarzyna Guz
IKIzabella Kopeć
Izabella Kopeć
ELElżbieta Lachert
Elżbieta Lachert
EBEwa Brojer
Ewa Brojer
Introduction : Pregnant women negative for human platelet antigen 1 a (HPA-1a) are at risk of alloimmunization with fetal HPA-1a antigen inherited from the father, and their offspring may develop fetal and neonatal alloimmune thrombocytopenia (FNAIT). The aim of this study was to analyze the...